XELJANZ / XELJANZ XR recall in Canada: Risk of thrombosis
In plain language
This recall involves XELJANZ and XELJANZ XR (tofacitinib) tablets sold in Canada. It's being recalled because of an increased risk of blood clots (thrombosis). Stop using the product and consult your healthcare professional for guidance.
What to do
- Stop using the product immediately.
- Consult your healthcare professional for medical advice.
- Monitor for signs of blood clots such as swelling, pain, or shortness of breath.
Get alerts for recalls like this
Get email alerts when new recalls affect products in this category.
Affected products
XELJANZ (tofacitinib)
Model: 5 mg and 10 mg tablets
XELJANZ XR (tofacitinib)
Model: 11 mg extended-release tablets
Why this matters
Risk of thrombosis (blood clots)
Do I have this product?
This recall only applies to specific products. Follow the steps below to check.
- 1
Check the product name
Make sure your product name matches one of the affected products listed above.
- 2
Check the model number
Model numbers are typically on the product label or packaging.
Affected models: 11 mg extended-release tablets, 5 mg and 10 mg tablets
If your product matches one or more of the details above, it may be affected by this recall.
If your product does not match these details, it is not affected by this recall.
When in doubt, always check the official notice.
Frequently Asked Questions
Why was this product recalled?
Risk of thrombosis (blood clots)
What should consumers do?
Stop using the product immediately. Consult your healthcare professional for medical advice. Monitor for signs of blood clots such as swelling, pain, or shortness of breath.
Where was the product sold?
This product was sold in Canada. For specific retailers or distribution areas, please check the official recall notice linked on this page.
Is there a health risk?
Yes, there may be a health risk. Risk of thrombosis (blood clots)
When was this product recalled?
This product was recalled on December 2, 2019.
Is the XELJANZ / XELJANZ XR brand affected by this recall?
Yes, XELJANZ / XELJANZ XR products are affected by this recall. This recall involves XELJANZ and XELJANZ XR (tofacitinib) tablets sold in Canada. It's being recalled because of an increased risk of blood clots (thrombosis). Stop using the product and consult your healthcare professional for guidance.